Healio13h
Winrevair PAH trial stopped due to earlier ‘robust evidence’
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...
Merck’s Winrevair: A Catalyst for Stock Growth Amid Promising Clinical Developments
In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
Monthly Prescribing Reference13h
Sotatercept Trial Ends Due to Positive Clinical Program Efficacy Data
A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...
Jim Cramer on Merck & Co., Inc. (MRK): ‘I Bet The Numbers Will Be Good, But There Are Other Issues’
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...